이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

자궁내막암, 난소암 및 자궁경부암 검출에 메틸화 DNA 마커(MDM) 활용 (ECHO)

2026년 11월 4일 업데이트: Mayo Clinic

자궁내막암, 난소암 및 자궁경부암 검출에 메틸화 DNA 마커(MDM) 활용: 2상 임상 연구

The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma.

This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in vaginal fluid and 2) ovarian cancer (OC) in plasma and vaginal fluid. Additionally, it defines necessary Phase I MDM-based cancer detection and exploratory aims to test novel cervical cancer (CC) MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.er detection and exploratory aims to test novel cervical cancer MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Detection of endometrial, ovarian, and cervical cancers at an early stage vastly increases the chances of cure and may also avert morbidity secondary to surgical staging, radiation, and/or chemotherapy. Despite the great successes of cervical cancer screening, comparable early detection methods for other gynecologic cancers and their precursors are not available. While nearly 1.5 million women per year in the United States are evaluated for abnormal uterine bleeding (AUB) or postmenopausal bleeding (PMB), the most common symptom of endometrial cancer, most undergo an invasive diagnostic biopsy with the finding of benign etiology.

Vaginal bleeding is often the only presenting symptom of women ultimately diagnosed with endometrial cancer (EC) or its precursor lesion, endometrial hyperplasia(EH). More than 90% of women with EC present with vaginal bleeding. Cervical cancer and cervical dysplasia can present as intermenstrual bleeding, post-coital bleeding, or other abnormal vaginal bleeding. However, most women who present with AUB or PMB have a benign etiology.

There are approximately 70 million women ≥45 years of age in the United States based on the most recent census data. Between 4-11% of women will be worked up for perimenopausal AUB or PMB in their lifetime. As only 5-10% of those women will have an EC or EH, there is a great clinical need for a less invasive clinical diagnostic test that can reliably distinguish between benign uterine bleeding and bleeding associated with an underlying endometrial cancer, cervical cancer, or a precursor lesion.

연구 유형

관찰

등록 (추정된)

3110

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Arizona
      • Phoenix, Arizona, 미국, 85054
        • 모병
        • Mayo Clinic
        • 수석 연구원:
          • Kristina A. Butler, M.D.
        • 연락하다:
    • Florida
      • Jacksonville, Florida, 미국, 32224
        • 모병
        • Mayo Clinic
        • 연락하다:
        • 수석 연구원:
          • Tri A. Dinh, M.D.
      • Miami, Florida, 미국, 33173
        • 모병
        • Genoma Research, Inc.
        • 연락하다:
        • 수석 연구원:
          • Guillermo Lievano, D.O.
        • 부수사관:
          • Itsel Cardenas, PhD, APRN
      • Miami, Florida, 미국, 33156
        • 모집하지 않고 적극적으로
        • My GYN Care
      • Orlando, Florida, 미국, 32806
      • Pembroke Pines, Florida, 미국, 33029
        • 모집하지 않고 적극적으로
        • Signature Women's Healthcare, LLC
      • Sarasota, Florida, 미국, 34239
        • 모병
        • Sarasota Memorial Health Care System
        • 수석 연구원:
          • Toni P Kilts, D.O.
        • 연락하다:
    • Georgia
      • Atlanta, Georgia, 미국, 30318
        • 모병
        • Piedmont Healthcare
        • 연락하다:
        • 수석 연구원:
          • Leda Portia A. Gattoc, M.D.
    • Illinois
      • Chicago, Illinois, 미국, 60637
      • Evergreen Park, Illinois, 미국, 60805
        • 모집하지 않고 적극적으로
        • Providea Health Partners, LLC
    • Louisiana
      • New Orleans, Louisiana, 미국, 70121
        • 모병
        • Ochsner Clinic Foundation
        • 수석 연구원:
          • Diogo Torres, M.D.
        • 연락하다:
    • Michigan
      • Detroit, Michigan, 미국, 48202
        • 모병
        • Henry Ford Health
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Ilinca Lupea, M.D.
      • Saginaw, Michigan, 미국, 48602
        • 모병
        • Valley OB-GYN Clinic
        • 연락하다:
        • 수석 연구원:
          • Olivia A. Phifer-Combs, M.D.
    • Minnesota
      • Rochester, Minnesota, 미국, 55905
        • 모병
        • Mayo Clinic
        • 연락하다:
        • 수석 연구원:
          • Jamie N. Bakkum-Gamez, MD
    • Mississippi
      • Jackson, Mississippi, 미국, 39213
        • 모병
        • University of Mississippi Medical Center
        • 수석 연구원:
          • Rodney Rocconi, M.D.
        • 연락하다:
        • 연락하다:
    • New York
      • Howard Beach, New York, 미국, 11414
        • 모병
        • The Woman's Health Pavilion
        • 연락하다:
        • 수석 연구원:
          • Andre H. Saad, M.D.
      • Westbury, New York, 미국, 11590
        • 모병
        • The Woman's Health Pavilion
        • 연락하다:
        • 수석 연구원:
          • Andre H. Saad, M.D.
    • North Dakota
      • Grand Forks, North Dakota, 미국, 58206
        • 모병
        • Altru Health System
        • 수석 연구원:
          • Collette Lessard, M.D.
        • 연락하다:
    • Ohio
      • Cleveland, Ohio, 미국, 44195
        • 모병
        • Cleveland Clinic Foundation
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Michelle L. Kuznicki, M.D.
    • Texas
      • Houston, Texas, 미국, 77018
        • 모병
        • Total Women's Care of the Heights
        • 수석 연구원:
          • Vonne Jones, M.D.
        • 연락하다:
      • Katy, Texas, 미국, 77450
        • 모병
        • Medical Colleagues of Texas, LLP
        • 연락하다:
        • 수석 연구원:
          • Kelly A. McCullagh, M.D.
    • Virginia
      • Richmond, Virginia, 미국, 23219
        • 모병
        • Virginia Commonwealth University/ Massey Cancer Center
        • 수석 연구원:
          • Chelsea Salyer, M.D.
        • 연락하다:
        • 연락하다:
    • Wisconsin
      • Eau Claire, Wisconsin, 미국, 54703
        • 모병
        • Mayo Clinic Health System - Northwest Wisconsin
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Blenda Yun, M.D.
      • La Crosse, Wisconsin, 미국, 54601
        • 모병
        • Mayo Clinic Health System - Southwest Wisconsin
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Rebecca A. Scarseth, D.O.
      • Milwaukee, Wisconsin, 미국, 53226
        • 모집하지 않고 적극적으로
        • Medical College of Wisconsin

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

샘플링 방법

비확률 샘플

연구 인구

Patients presenting to a GYN or GYN Surgery Clinic for evaluation of symptoms or for consultation and planned procedures as outlined in the seven study cohort descriptions.

설명

Inclusion Criteria for Cohort 1:

Patients will be ≥45 years of age and meet one of the following criteria:

  • Abnormal uterine bleeding
  • Postmenopausal bleeding

OR

Patients ages 18 - 44 years of age and meet these criteria

  • Abnormal uterine bleeding
  • One risk factor for endometrial cancer (BMI ≥30 or PCOS or Tamoxifen use)

Exclusion Criteria for Cohort 1:

  • Prior hysterectomy
  • Current known pregnancy diagnosis
  • Any prior pelvic or vaginal radiotherapy
  • Any prior cancer (except basal cell skin cancer) within the past 5 years
  • Chemotherapy within the past 5 years
  • Current biopsy-proven cervical, vaginal, or vulvar cancer or lower genital tract dysplasia
  • Current biopsy-proven endometrial cancer or endometrial hyperplasia
  • Current biopsy-proven benign endometrial polyp
  • Endometrial biopsy/sampling within the preceding 1 month showing benign endometrium

Inclusion Criteria for Cohort 2:

Patients will be ≥18 years of age and meet at least one of the following criteria:

  • Presence of biopsy-proven EC (any histology, including uterine carcinosarcoma) and surgical intervention planned. Surgical intervention can include any of the following: hysterectomy, D&C, hysteroscopic resection
  • Biopsy showing AEH or EIN with surgical intervention planned. Surgical intervention can include any of the following: hysterectomy, D&C, hysteroscopic resection, etc)

Exclusion Criteria for Cohort 2:

  • Undergoing surgical procedure for recurrent or metastatic EC
  • Received preoperative neoadjuvant chemotherapy or radiotherapy for current EC diagnosis
  • Prior hysterectomy
  • Current known pregnancy diagnosis
  • Prior or current biopsy-proven cervical cancer
  • Presence of concomitant biopsy-proven cervical dysplasia
  • Any prior pelvic or vaginal radiotherapy
  • Any prior cancer (except basal cell skin cancer) within the past 5 years
  • Chemotherapy within the past 5 years
  • Prior intervention or surgery with intent to completely remove the target pathology

Inclusion Criteria for Cohort 3:

Patients will be ≥18 years of age, have a cervix and meet at least one of the following criteria:

  • History of current abnormal cervical/endocervical Pap test for which the patient is presenting for colposcopy
  • Cervical mass identified on physical exam and patient referred for cervical biopsy, even if colposcopy not recommended or indicated
  • Planned clinically indicated surgical excisional biopsy or removal of the cervix (cold knife cone, LEEP, hysterectomy) for abnormal Pap test, cervical dysplasia, cervical mass, or biopsy-proven invasive cervical cancer (adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, or less common primary cervical carcinomas all eligible)

Exclusion Criteria for Cohort 3:

  • History of pelvic or vaginal radiotherapy
  • Prior total hysterectomy (cervix removed) for any indication
  • Current known pregnancy diagnosis
  • Cervical mass biopsy-proven to be EC or a cancer metastatic from a non-cervical origin
  • Any prior cancer (except basal cell skin cancer) within the past 5 years
  • Chemotherapy within the past 5 years
  • Patients presenting for colposcopy as part of lower genital tract dysplasia or cancer surveillance after prior curative intent treatment and no current Pap abnormality or cervical mass
  • Prior intervention or surgery with intent to completely remove the target pathology for the current lesion / diagnosis during the current episode

Inclusion Criteria for Cohort 4:

Patients will be ≥45 years of age and should meet at least one of the following criteria:

  • Undergoing hysterectomy with biopsy-proven or clinically presumed (based on imaging and/or clinical symptoms) benign gynecologic or uterine pathology of fibroids, endometriosis, adenomyosis, or benign endometrial polyps.
  • Undergoing any gynecologic surgery in which a benign pathologic tissue diagnosis of fibroids, endometriosis, adenomyosis, or benign endometrial polyp is anticipated to be confirmed.

Exclusion Criteria for Cohort 4:

  • Endometrial biopsy or office hysteroscopy within 2 weeks preceding the planned gynecologic surgery procedure for fibroids, endometriosis, benign endometrial polyps, or adenomyosis
  • Any surgery within the past 3 months
  • Prior hysterectomy
  • Current known pregnancy diagnosis
  • Prior or current biopsy-proven gynecologic cancer
  • Current biopsy-proven AEH/EIN, cervical, vaginal, or vulvar dysplasia
  • Prior pelvic or vaginal radiotherapy
  • Any prior cancer (except basal cell skin cancer) within the past 5 years
  • Chemotherapy within the past 5 years
  • Undergoing hysterectomy for prolapse without a coexisting known or presumed benign uterine pathologic diagnosis of fibroids, endometriosis, benign endometrial polyps, or adenomyosis
  • Prior intervention or surgery with intent to completely remove the target pathology for the current lesion / diagnosis during the current episode

Inclusion Criteria for Cohort 5:

Patients with a uterus will be ≥45 years of age and should meet the following criteria:

  • Presenting for GYN wellness exam, ± Pap test
  • No change in medical conditions, new diagnoses, or new medications within the past 6 months

Exclusion Criteria for Cohort 5:

  • Pap test or cervical biopsy within the past 1 month
  • Endometrial biopsy or office hysteroscopy within the past 1 month
  • Any surgery within the past 3 months
  • Prior hysterectomy
  • Current known pregnancy diagnosis
  • Prior or current biopsy-proven gynecologic cancer
  • Current biopsy-proven AEH/EIN, cervical, vaginal, or vulvar dysplasia
  • Prior pelvic or vaginal radiotherapy
  • Any prior cancer (except basal cell skin cancer) within the past 5 years
  • Chemotherapy within the past 5 years
  • Criteria met for inclusion in any of the other study cohorts

Inclusion Criteria for Cohort 6:

Patients ≥50 years of age and:

  • Postmenopausal
  • At least 1 intact ovary
  • Diagnosis of an adnexal mass or a clinical suspicion of early-stage ovarian cancer (including fallopian tube cancer)
  • Planned surgery for the adnexal mass
  • For vaginal fluid collection, patient must have a uterus, cervix and at least 1 intact fallopian tube* (without prior tubal ligation/occlusion)

Exclusion criteria for Cohort 6:

  • Any current or prior cancer diagnosis (except basal cell or squamous cell skin cancer, non-gyn)
  • Chemotherapy for cancer treatment within the past 5 years prior to collection
  • Clinically suspected advanced stage ovarian cancer (Stage III or IV) on presentation, if known prior to specimen collection
  • Surgical candidates for recurrent ovarian cancer
  • History of pelvic or vaginal radiation therapy
  • Known current synchronous endometrial cancer or hyperplasia
  • Known current cervical, vaginal, or vulvar dysplasia

Inclusion criteria for Cohort 7:

Women will be ≥18 years of age and meet the following criteria:

  • Presence of clinically probable ovarian, fallopian tube, or primary peritoneal cancer (all under the umbrella of OC) based on clinical findings of any/all of the following: imaging showing adnexal and/or abdominal masses consistent with probable ovarian cancer, omental caking, elevated CA125, ascites, imaging-guided biopsy consistent with OC pathology
  • Newly diagnosed with ovarian, fallopian tube or primary peritoneal cancer without neoadjuvant therapy
  • At least one intact ovary
  • For vaginal fluid collection, patient must have a uterus, cervix and at least 1 intact fallopian tube* (without prior tubal ligation/occlusion)

Exclusion criteria for Cohort 7:

  • Patients with recurrent OC
  • Any current or prior cancer diagnosis (except basal cell or squamous cell skin cancer, non-gyn) within the past 5 years
  • Chemotherapy for cancer treatment within the past 5 years prior to collection
  • History of pelvic or vaginal radiation therapy
  • Known current synchronous endometrial cancer or hyperplasia
  • Known current cervical, vaginal, or vulvar dysplasia
  • Current known pregnancy diagnosis

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
Cohort 1 - AUB / PMB

Patients ≥45 years of age, presenting with abnormal uterine bleeding (AUB) or post-menopausal bleeding (PMB). Patients ages 18 - 44 years of age, presenting with abnormal uterine bleeding (AUB) and a risk factor for endometrial cancer (BMI ≥30 or PCOS or Tamoxifen use). These presenting symptoms clinically warrant evaluation such as an endometrial biopsy to assess for underlying endometrial cancer, endometrial hyperplasia or other endometrial pathology.

A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.

다른 이름들:
  • 질액

A blood sample will be collected from each participant prior to undergoing any exams or procedures.

Cohort 2 - Biopsy-proven EC or AEH or EIN

Patients ≥18 years of age with biopsy-proven endometrial cancer (EC), atypical endometrial hyperplasia (AEH), or endometrial intraepithelial neoplasia (EIN) presenting for surgical management of their endometrial pathology.

A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.

다른 이름들:
  • 질액

A blood sample will be collected from each participant prior to undergoing any exams or procedures.

Cohort 3 - Cervix pathology

Patients ≥18 years of age presenting for a clinically indicated colposcopy, cervical biopsy, or surgical excision, as follow-up for an abnormal Pap test or cervical mass identified on physical exam. Final clinical diagnoses within this cohort may include mild cervical intraepithelial neoplasia (CIN 1), moderate and/or severe CIN (CIN 2/3), adenocarcinoma in situ (AIS), invasive cervical cancers (adenocarcinoma or squamous cell carcinoma), or possibly benign findings.

A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.

다른 이름들:
  • 질액

A blood sample will be collected from each participant prior to undergoing any exams or procedures.

Cohort 4 - Benign Uterine Pathology

Patients with any of four benign gynecologic conditions including: uterine fibroids, benign endometrial polyps, adenomyosis and endometriosis. All patients enrolled in this cohort will be undergoing clinically indicated gynecologic surgery (hysterectomy, myomectomy, polypectomy, or laparoscopic tissue excision) for the specific benign gynecologic condition. Verification of the final benign diagnosis will be based on pathology diagnosis of clinically-indicated tissue removed during surgery.

A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.

다른 이름들:
  • 질액

A blood sample will be collected from each participant prior to undergoing any exams or procedures.

Cohort 5 - Healthy Control Women

Healthy patients with a uterus, ≥45 years of age presenting for GYN wellness exam to serve as a control group. These patients will have no clinically evident gynecologic precancers, gynecologic cancers, or clinically evident or symptomatic benign gynecologic conditions. These patients will not have known or clinically suspected AUB, PMB, fibroids, endometriosis, benign endometrial polyps, or adenomyosis, nor will they have any active gynecologic or non-gynecologic acute medical conditions.

A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.

다른 이름들:
  • 질액

A blood sample will be collected from each participant prior to undergoing any exams or procedures.

Cohort 6- Isolated Adnexal Mass Cohort (ovarian or fallopian mass)

Patients ≥50 years of age and postmenopausal (12 months since LMP or available blood hormone levels confirming postmenopausal status) and an isolated adnexal mass or isolated bilateral adnexal masses being surgically removed. These patients may have a final diagnosis of any of the following: benign ovarian neoplasm, borderline tumor of the ovary, or clinically early-stage OC.

A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.

다른 이름들:
  • 질액

A blood sample will be collected from each participant prior to undergoing any exams or procedures.

Cohort 7 - OC Cohort - Biopsy proven or clinically suspected ovarian cancer (OC)

Patients ≥18 years of age with ovarian cancer (OC) (clinically probable based on distribution of pelvic/abdominal masses on imaging, elevated CA-125, ascites, and/or imaging-guided biopsy proven) presenting for neoadjuvant chemotherapy or primary surgical management (debulking or staging) of their OC. The umbrella of OC also includes fallopian tube cancer and primary peritoneal cancer. All histologies are eligible for enrollment.

A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.

다른 이름들:
  • 질액

A blood sample will be collected from each participant prior to undergoing any exams or procedures.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Develop predictive models from a panel of EC-specific MDMs and validate their performance in identifying underlying EC and AEH within vaginal fluid in a larger, more diverse cohort.
기간: 18 months

Complete a phase II biomarker development study of a methylated DNA marker (MDM)-based endometrial cancer detection test performed on vaginal fluid. The phase II aspect of this biomarker development study will narrow the number of endometrial cancer MDMs within the biomarker panel in order to optimize the next phase of test development.

18 months
Develop predictive models from a panel of OC-specific MDMs and validate their performance in identifying underlying OC within vaginal fluid and plasma in a larger, more diverse cohort.
기간: 18 months

Complete a phase II biomarker development study of a methylated DNA marker (MDM)-based ovarian cancer detection test performed on vaginal fluid. The phase II aspect of this biomarker development study will narrow the number of ovarian cancer MDMs within the biomarker panel in order to optimize the next phase of test development.

18 months

2차 결과 측정

결과 측정
측정값 설명
기간
Using 95% specificity cutoffs of the final MDM EC panel, determine the false positive rate among women undergoing surgical removal of common benign gynecologic pathology
기간: 18 months

As part of this biomarker test development, understanding whether common non-cancerous uterine or gynecologic conditions may also lead to the finding of currently apparent endometrial cancer-specific MDMs in vaginal fluid is critical in determining specificity, positive predictive value, and negative predictive value of the test.

18 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Jamie N. Bakkum-Gamez, M.D., Mayo Clinic

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 8월 3일

기본 완료 (추정된)

2027년 7월 30일

연구 완료 (추정된)

2027년 9월 30일

연구 등록 날짜

최초 제출

2021년 9월 11일

QC 기준을 충족하는 최초 제출

2021년 9월 11일

처음 게시됨 (실제)

2021년 9월 21일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 4일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 20-012833

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .